Japan and South East Asia show rapid expansion, according to CPhI

The market in South East Asia is undergoing a rapid period of development, while Japan’s pharma market is one of the most mature in the world. That is the feedback from UBM EMEA, organizer of CPhI South East Asia and CPhI Japan events which were held in April.

At CPhI Japan, over half of the exhibiting companies were from overseas, surprising considering Japan’s pharma market has long been considered domestically focused. Moreover, with the market’s recent awakening to the value of generics to help supply the rising health care demand, international partnerships are fast becoming a driving force for Japan. A further rise is forecast.

In contrast, the Indonesian pharma market has undergone remarkable growth and is now acting as the central hub for pharmaceuticals in the region. The CPhI South East Asia feedback suggests that Indonesia will not only see a significant growth in pharma manufacturing domestically, but will also become a key exporter to nearby economies.